Abstract
Background: Pseudomyxoma peritonei (PMP) is a rare disease characterized by mucinous ascites and peritoneal implants originated from a ruptured appendiceal neoplasm. Current standard treatment consists of cytoreduction and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), but treatment recurrences occur in 20-30% of patients. Involvement of the inguino-crural region by mucinous material has been described both at disease diagnosis and as disease relapse. It has been reported that follow-up with tumor markers and MRI can detect locoregional relapse in the form of mucinous deposits of smaller size than those detected by CT scan.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
